DKP-21103 is under clinical development by Dongkwang Pharma and currently in Phase I for Duodenal Ulcer. According to GlobalData, Phase I drugs for Duodenal Ulcer have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DKP-21103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DKP-21103 overview
DKP-21103 is under development for the treatment of unspecified cardiovascular disorders, gastric ulcers and duodenal ulcers.
Dongkwang Pharma overview
Dongkwang Pharma is a manufacturer of pharmaceutical products. The company offers products in the therapeutic areas such as anti-inflammatory, analgesics, central nervous system, musculo-skeletal system, anti-infectives, corticosteroids, antihistamines, gastrointestinal system, genitor-urinary system, cardiovascular system, anti-erectile dysfunction, dermatologicals, and endocrine and metabolic system, among others. It also provides respiratory system and antidepressants. The company conducts research and development in the areas of planning and research of new formulations, development and research of first generic products, research on improvement and optimization of medicine manufacturing process, development of new product analysis methods and method validation, establishment of approval standard for pharmaceuticals and standard for test methods, search for new active materials, and research and development of new medicine originating from natural substances. Dongkwang Pharma is headquartered in Seoul, South Korea.
For a complete picture of DKP-21103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
